^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:HER2 Positive Breast Cancer
    Drug:Pozenveo (poziotinib) (HER2 inhibitor, HER4 inhibitor, pan-EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

    Excerpt:
    ...- Patient must have confirmed HER2 overexpression or gene-amplified tumor via immunohistochemistry [IHC] with IHC 3+ or IHC 2+ with confirmatory fluorescence in situ hybridization [FISH]+ or [ISH]+...
    Trial ID:
    NCT03429101
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Role of HER2 copy number amplification and PI3K pathway as a biomarker for patients with HER2+ MBC treating with Poziotinib, pan-HER TKI.

    Published date:
    05/16/2018
    Excerpt:
    HER2 CN amplification and PIK3CA pathway alteration had an effect on the clinical outcome of patients with HER2+ MBC treated with poziotinib.
    DOI:
    10.1200/JCO.2018.36.15_suppl.e13009
    Trial ID:
    NCT02418689